

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**☐ 1. Document ID: WO 9723219 A1

L45: Entry 1 of 2

File: EPAB

Jul 3, 1997

PUB-NO: WO009723219A1

DOCUMENT-IDENTIFIER: WO 9723219 A1

TITLE: SUSTAINED-RELEASE MICROGRANULES CONTAINING DILTIAZEM AS THE ACTIVE PRINCIPLE

PUBN-DATE: July 3, 1997

INVENTOR-INFORMATION:

NAME

COUNTRY

DEBREGEAS, PATRICE

FR

LEDUC, GEGARD

FR

OURY, PASCAL

FR

SUPLIE, PASCAL

FR

INT-CL (IPC): A61 K 31/55; A61 K 9/50

EUR-CL (EPC): A61K031/55; A61K009/50

ABSTRACT:

CHG DATE=19970826 STATUS=O>Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	INWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 2. Document ID: US 20020182253 A1 WO 9723219 A1 FR 2742660 A1 ZA 9610776 A AU 9711983 A NO 9802738 A EP 868184 A1 CN 1207681 A BR 9612225 A NZ 324739 A HU 9904129 A2 JP 2000506500 W AU 721949 B KR 99076717 A MX 9805121 A1 US 6228395 B1 US 6383516 B1

L45: Entry 2 of 2

File: DWPI

Dec 5, 2002

DERWENT-ACC-NO: 1997-350775

DERWENT-WEEK: 200301

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Sustained release microgranules comprise carrier coated with active layer of diltiazem, surfactant and binder, then covered with release layer - useful in treatment of arterial hypertension, providing solubilisation and absorption of active agent despite absence of water-soluble acid

INVENTOR: DEBREGEAS, P; LEDUC, G ; OURY, P ; SUPLIE, P .

PRIORITY-DATA: 1995FR-0015361 (December 22, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020182253 A1	December 5, 2002		000	A61K031/554
<u>WO 9723219 A1</u>	July 3, 1997	F	070	A61K031/55
FR 2742660 A1	June 27, 1997		015	A61K031/55
ZA 9610776 A	September 23, 1997		070	A61K000/00
AU 9711983 A	July 17, 1997		000	B42D015/10
NO 9802738 A	August 21, 1998		000	A61K000/00
EP 868184 A1	October 7, 1998	F	000	A61K031/55
CN 1207681 A	February 10, 1999		000	A61K031/55
BR 9612225 A	July 13, 1999		000	A61K031/55
NZ 324739 A	January 28, 2000		000	A61K031/55
HU 9904129 A2	April 28, 2000		000	A61K031/55
JP 2000506500 W	May 30, 2000		070	A61K031/554
AU 721949 B	July 20, 2000		000	A61K031/55
KR 99076717 A	October 15, 1999		000	A61K031/55
MX 9805121 A1	February 1, 1999		000	A61K031/55
US 6228395 B1	May 8, 2001		000	A61K009/58
US 6383516 B1	May 7, 2002		000	A61K009/58

B1 , US 6383516 B1 INT-CL (IPC): A61K 0/00; A61K 9/16; A61K 9/24; A61K 9/50; A61K 9/52; A61K 9/54; A61K 9/58; A61K 31/55; A61K 31/554; A61K 47/20; A61K 47/24; A61P 9/12; B32B 7/06; B32B 7/12; B42D 15/10; C07D 281/10; C09J 7/02

ABSTRACTED-PUB-NO: US 6228395B

BASIC-ABSTRACT:

Sustained release microgranules comprise a layer to ensure sustained release of an active agent and a neutral, granular carrier coated with an active layer containing diltiazem or one of its salts, a surfactant and binder.

The layer provides slow or rapid release of the active agent. The layer providing slow sustained released is itself coated with a second layer containing the active agent, surfactant and binder and over this an external layer for rapid release of (I) contained in the second active layer. An intermediate layer is optionally intercalated between the slow release layer and its coating.

USE - Diltiazem is a calcium antagonist which is used in the treatment of arterial hypertension.

ADVANTAGE - The microcapsules are easy to make and despite the absence of a water-soluble organic acid, active agent solubilisation and absorption levels are equivalent to those achieved in the presence of an acid.

ABSTRACTED-PUB-NO:

US 6383516B EQUIVALENT-ABSTRACTS:

Sustained release microgranules comprise a layer to ensure sustained release of an active agent and a neutral, granular carrier coated with an active layer containing diltiazem or one of its salts, a surfactant and binder.

The layer provides slow or rapid release of the active agent. The layer providing slow sustained released is itself coated with a second layer containing the active agent, surfactant and binder and over this an external layer for rapid release of (I) contained in the second active layer. An intermediate layer is optionally intercalated between the slow release layer and its coating.

USE - Diltiazem is a calcium antagonist which is used in the treatment of arterial hypertension.

ADVANTAGE - The microcapsules are easy to make and despite the absence of a

water-soluble organic acid, active agent solubilisation and absorption levels are equivalent to those achieved in the presence of an acid.

Sustained release microgranules comprise a layer to ensure sustained release of an active agent and a neutral, granular carrier coated with an active layer containing diltiazem or one of its salts, a surfactant and binder.

The layer provides slow or rapid release of the active agent. The layer providing slow sustained release is itself coated with a second layer containing the active agent, surfactant and binder and over this an external layer for rapid release of (I) contained in the second active layer. An intermediate layer is optionally intercalated between the slow release layer and its coating.

USE - Diltiazem is a calcium antagonist which is used in the treatment of arterial hypertension.

ADVANTAGE - The microcapsules are easy to make and despite the absence of a water-soluble organic acid, active agent solubilisation and absorption levels are equivalent to those achieved in the presence of an acid.

WO 9723219A

Full Title Citation Front Review Classification Date Reference Sequences Attachments

FWC Draw Desc Clip Img Image

Generate Collection

Print

Term	Documents
WO-9723219\$	0
WO-9723219-A1.DWPI,EPAB,JPAB,USPT,PGPB.	2
WO-9723219\$.DID..USPT,PGPB,JPAB,EPAB,DWPI.	2
(WO-9723219\$.DID.).USPT,PGPB,JPAB,EPAB,DWPI.	2

Display Format:

REV

Change Format

[Previous Page](#)

[Next Page](#)

WEST Search History

DATE: Tuesday, March 18, 2003

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L48	us-6383516\$.did.	2	L48
L47	us-6228395\$.did.	2	L47
L46	wo-6228395\$.did.	0	L46
L45	wo-9723219\$.did.	2	L45
L44	wo-59723219\$.did.	0	L44
L43	us-5576022\$.did.	2	L43
L42	L40 and l35	26	L42
L41	L40 and l36	36	L41
L40	L39 and l38	36	L40
L39	l32 and l8	450	L39
L38	l36 and l37	356	L38
L37	l11 or l12	1481284	L37
L36	l32 and l33	363	L36
L35	(immediate or burst or rapid) release	7390	L35
L34	l31 and l8	6633	L34
L33	l31 and (l23 or l14)	11873	L33
L32	l30 and core	5827	L32
L31	layer or coat\$3	3610179	L31
L30	L29 or l28	44280	L30
L29	molsidamine or indomethacine or sulindac or indoprofen or krtoprofrn or flurbiprofen or fenbufen or fluprofen or diclofenac or tiaprofenic or naproxen or mizolastin or terbulaline or salbutamol or betamethasone or prednisone or methylprednsone or dexamethasone or prednisolone or sumatriptan or naratriptan or cimetidine or ranitidine of famotidine or nizatidine or omeprozole or omeprazole or morphine or fenoprofen or ibuprofen or ketoprofen or alclofenac or mefenamic or alfuzosin or tamulosin or prazosin or levodopa or methylropa	33210	L29
L28	diltiazem or diltazem or theophylline or felopdipine or verapamil or clonidine or acebutolol or alprenolol or betaxolol or metoprolol or nadolol or propranolol or timolol or captopril or enalapril of fosinopril or tiapamil or gallopml or amlodipine or nitrendipine or nisoldipine or nicardipine or felodipine	17837	L28
L27	l22 and l9	99	L27
L26	l22 and l10	0	L26
L25	l14 and l22	24	L25
L24	L23 and l22	22	L24
L23	methacrylate copolymer	16672	L23

L22	L21 and l13	147	L22
L21	L20 and l18	184	L21
L20	L19 and (l11 or l12)	140063	L20
L19	capsule or encapsul\$5	273415	L19
L18	L17 and l11	197	L18
L17	L16 and l8	209	L17
L16	l1 and l3 and l4	1623	L16
L15	l1 and l3 and l4 ad l5 and l8	0	L15
L14	eudragit RS! or eudragit rl!	446	L14
L13	hydroxypropylmethylcellulose or hydroxythylcellulose or polyvinylpyrrolidone	44629	L13
L12	tablet or minitabket or mini-tablet	145946	L12
L11	particle or pellet or bead or granule or spheroid	1408245	L11
L10	cocamidopropylbetaine	197	L10
L9	n-alkylglycine or c-alkylbetaine or n-alkylamidobetaine or n-alybetaine or phosphatidylcholine or lecithin	38328	L9
L8	l7 or l6	10432	L8
L7	dimethyl-didodecyl-ammonium bromide or dimethyldidodecylammonium bromide or benzalkonium chloride or cetylpyridinium chloride or cetrimide	10229	L7
L6	trimethyldimyristoylammonium propionate or trimethyl-dimyristoyl-ammonium propionate or dioctadecylammonium bromide or dioctadecyl-ammonium bromide or trimethylcetylammmonium bromide or trimethyl-cetyl-ammonium bromide	242	L6
L5	cation\$2 or zwitterion\$2	263438	L5
L4	surfactant	249951	L4
L3	active ingredient of active agent or pharmaceutical	257948	L3
L2	delayed release	6283	L2
L1	core same coat\$3	84092	L1

END OF SEARCH HISTORY